For many Mendelian phenotypes, identifi cation of the culprit gene and its alleles is often insuffi cient to understand the disease, as the penetrance of these alleles is largely dependent on the genetic background. Disease phenotype is therefore highly variable between indi vidu als and identifying socalled modifi er genes is an important step towards personalized medicine. Looking for modi fi er genes is one of the major challenges of modern human genetics, and there is a need for new simple comprehensive methods to identify these genes in an effi cient and unbiased fashion.
In this issue of Genome Medicine, the groups of Eliza beth Miller (Columbia University, NY, USA) and John Hartman (University of Alabama, AL, USA) des cribe a novel yeastbased model to search for modifi er genes involved in cystic fi brosis [1] . Th e authors introduce a mutation in yeast that is equivalent to the cystic fi brosis transmembrane conductance regulator (CFTR)ΔF508 human mutation, that is, deletion of phenylalanine at amino acid 580 of the CFTR protein. Using this yeast model, the authors perform a comprehensive search for genes that, when inactivated, suppress or exacerbate the phenotype resulting from this mutation. Th e authors describe it as a 'phenomic model' . Th is highthroughput phenotyping approach is quantitative and based on the synthetic genetic array method [2] .
Th e authors concentrated their study on CFTRΔF508, by far the most prevalent allele of CFTR, whose muta tions are responsible for cystic fi brosis. Indeed, CFTR ΔF508 is overrepresented among the more than 1,900 diff erent mutated alleles of CFTR identifi ed so far, as it accounts for more than 70% of them. Th is mutation impairs CFTR folding, leading to the defective traffi cking of this protein to the plasma membrane of secretory epithelial cells, where it normally functions as a chloride channel [3] . Instead of being properly addressed to the plasma membrane, the CFTRΔF508 protein is recog nized and degraded by protein quality control systems, such as the ubiquitinproteasome pathway. As a conse quence, a defi cit in chloride transport is observed that leads to dehydration and thickening of the secreted mucus, in particular in the airways. Th is in turn causes many lung infections and, ultimately, fatal respiratory failure. However, it has long been known that forced traffi cking of CFTRΔF508 to the plasma membrane for example, by growing cells at low temperature at least partly restores its function, because the CFTRΔF508 mutation does not have a strong impact on the actual biological function of the CFTR protein. Hence, every modifi er gene that suppresses or exacerbates the traffi ck ing defect of CFTRΔF508 would respectively decrease or increase the impact of the mutation in patients. Th e rationale of the yeastbased model for CFTRΔF508 was thus to recapitulate its defective folding and traffi cking by introducing an equivalent mutation into one of its yeast homologs, thereby allowing isolation of modifi er genes thanks to the tremendous power of yeast genetics.
Yeast as a tool and model for biomedical research
Yeast has long been used as a powerful model system for basic research aimed at deciphering the most funda mental cellular mechanisms. Over the past one or two decades, yeast has also been used as a model and tool for biomedical research. Th is use extends from the fi eld of diagnostics to drug discovery and production. For example, an elegant yet simple yeastbased assay has been developed for assessing the functionality of the tumor suppressor gene p53 [4] , a crucial piece of information with respect to the choice of treatment for many cancers. Yeast is also used to produce therapeutic compounds such as hydrocortisone, a major steroid for the pharma ceutical industry [5] . In addition, yeast is increasingly used for drug screening, in particular for human in herited disorders. In the simplest and most direct cases where a functional homolog of the affected protein in human exists in yeast, the identified mutations can be introduced at synonymous positions in the considered gene, as in neuropathy, ataxia and retinitis pigmentosa (NARP) syndrome, a devastating mitochondrial disease [6] .
R E S E A R C H H I G H L I G H T
More complex are the situations where no functional ortholog exists. In these cases, it is desirable to obtain a phenotype that is relevant or close to the pathologic mechanisms, such as for the prionbased diseases [7] or Huntington's disease [8] . However, in all of these models, the basic idea is always the same: obtaining a yeast phenotype that is relevant for the considered disorders and then looking for modifiers of this phenotype. These modifiers can be positive or negative (that is, they may either suppress or exacerbate the phenotype) and they Figure 1 . Flowchart of the synthetic genetic array-based method for identifying CFTR-ΔF508 modifier genes. The (a) Matα yor1ΔF haploid strain, which presents an intermediate level of oligomycin sensitivity between that of Yor1 null mutants and wild-type Yor1, is robotically crossed with a collection of (b) Mata haploid strains that are deleted for every single yeast gene. Then sporulation of the resulting diploids is induced and the haploid double mutants are robotically selected and (c) their level of resistance to oligomycin assessed. An increased (yor1ΔF, geneYΔ double mutant) or decreased (yor1ΔF, geneZΔ double mutant) resistance to oligomycin indicates genetic interaction between yor1ΔF and the corresponding gene deletion, thereby highlighting yor1ΔF modifier genes. These yeast genes reveal potential human modifier genes of CFTR-ΔF508, which then require further validation in human cells expressing CFTR-ΔF508. can be drugs or genes or any other biological or chemical moiety. In addition, forward chemical genetics approaches can be performed in yeast for the discovery of chemical probe targets [9] .
A yeast-based phenomic model for CFTR-ΔF508
No ortholog of CFTR exists in yeast, so to produce the phenomic model of cystic fibrosis described above another ATPbinding cassette (ABC) transporter of the same family as CFTR was required. Therefore, the equiva lent mutation (deletion of a phenylalanine) was intro duced in the synonymous position (670) of the Yor1 protein, an ABC transporter that is the primary determi nant of oligomycin resistance in yeast because it extrudes this toxic compound from the cell. The authors of this study then convincingly showed that the mutation had the same effect on the yeast protein as on human CFTR; that is, interfering with its proper trafficking to the plasma membrane and leading to its misfolding and reduced halflife. However, unlike CFTRΔF508, Yor1 ΔF670 does not retain membrane transport function, a problem that the authors circumvented by introducing a second mutation (R1116T) that restores partial pump function. Hence, Yor1ΔF670R1116T confers a partial oligomycin resistance that is intermediate between that of Yor1 null mutants and wildtype Yor1. Based on this socalled Yor1ΔF strain and using a synthetic genetic array method [2] , the authors then looked for modifier genes that, when inactivated, increase or decrease oligo mycin resistance of the Yor1ΔF strain. The rationale for this method is shown in Figure 1 . Briefly, the Yor1ΔF strain was mated to a deletion strain collection and double mutants were selected. Their respective growth rate in the presence of oligomycin was then assessed, thereby allowing comprehensive identification of syn the tic interactions between Yor1ΔF and all cellular pathways. Using this procedure, the authors highlighted cellular pathways and genes already known to modulate process ing of CFTRΔF in mammalian cells, like the proteasome or E3 ligase Ubc7/Qr18, two actors affecting the turnover of CFTRΔF508. This result represents a first validation of the phenomic model. In addition, other evolutionarily conserved pathways were also identified, like the recently discovered endoplasmic reticulum mem brane complex [10] . The involvement of this pathway in trafficking misfolded ABC transporters was validated by a small interfering RNA approach in a human cell line expressing CFTRΔF508. Therefore, it seems that this elegant yeast based method constitutes a valuable tool for investigating gene interaction networks that can modulate cystic fibrosis disease severity, and further enable the identifi cation of socalled modifier genes. This seminal work by the teams of Elizabeth Miller and John Hartman constitutes a proofofconcept that yeast based phenomic approaches allow for the identi fication of modifier genes for human inherited disorders, provided that the main phenotypical consequences result ing from the causal mutations can be recapitulated in yeast.
Therefore, whilst brewer's yeast offers the opportunity to share a couple of pints at happy hour, favoring social interactions between people, it also provides the perfect environment for flirting with human genes involved in inherited disorders.
